Korean Journal of Pediatrics 2004;47(6):647-655.
Published online June 15, 2004.
The Effects of Gonadotropin-Releasing Hormone Agonists on Final Height and its Related Factors in Patients with True Precocious Puberty
Sung Yeon Ahn, Jae Ho Yoo, Choong Ho Shin, Sei Won Yang
Department of Pediatrics, College of Medicine, Seoul National University, Seoul, Korea
진성 성조숙증 환아에서 Gonadotropin-Releasing Hormone Agonists의 치료가 최종 성인 신장에 미치는 영향 및이와 관련된 인자들에 관한 연구
안성연, 류재호, 신충호, 양세원
서울대학교 의과대학 소아과학교실
Sei Won Yang, Email: growth@snu.ac.kr
: The aim of this study was to evaluate the effects of treatment with GnRH agonists on final height(FH) and the influencing factors on height gains.
: Twenty-five girls and five boys with true precocious puberty, who were treated with GnRH agonists for more than one year and had attained final height, were evaluated retrospectively. We analysed auxological parameters at diagnosis, at the end of treatment, and at the attainment of final height, and calculated height gains.
: FH SDS was significantly higher than predicted adult height(PAH) SDS at diagnosis (-0.91?.32, vs. -1.80?.39, P<0.01). A group of initial PAH below the range of target height(TH) attained significantly more height gains and increments of height SDS than those in a group of initial PAH within the range of TH(8.37?.56 cm vs. 1.38?.42 cm, P<0.01; 1.30?.74 vs. 0.35?.28, P<0.05). Height gains were positively correlated with bone age advancement at diagnosis and height velocity during the first year of treatment(r=0.528, P<0.01 and r=0.454, P<0.05), while height gains were negatively correlated with initial PAH and bone age increments during treatment(r=-0.485, P< 0.05 and r=-0.613, P<0.01).
: This study suggests that GnRH agonist therapy for children with true precocious puberty improves the final height, and height gains are positively affected by bone age advancement at diagnosis and growth velocity during the first year of therapy, and negatively affected by PAH at diagnosis and degree of bone maturation during therapy.
Key Words: Puberty, Precocious, Gonadorelin agonist, Body height

METRICS Graph View
  • 2,508 View
  • 27 Download

Close layer
prev next